When used with traditional chemotherapeutic drugs, SIRT1 and SIRT2 inhibitors have the potential to overcome drug resistance during the treatment of HCC due to the down-regulation of P-gp and MRP3 in HepG2 cells 307. Here, SIRT1 is linked to hepatocellular carcinoma.